Vancouver, BC – TheNewswire - February 21, 2025 – TAAT Global Alternatives, Inc. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT”) is pleased to announce that, further to its news release dated January 27, 2025, it has closed the acquisition of Premium Products LLC (“Premium Products”).

As consideration for the acquisition of all the outstanding shares of Premium Products, the Company issued an aggregate of 10,882,353 common shares (“Consideration Shares”) of TAAT, at a deemed price of $0.17 per share to the members of Premium Products.

The Consideration Shares are subject to a hold period of four months and one day from the date of issuance, in accordance with the National Instrument 45-106 (Prospectus Exemptions) and the following resale restrictions as set out by the Canadian Securities Exchange (the “CSE”):

i.        25% of the securities will be released upon the filing of the Company’s next financial statements that include Premium Products on the balance sheet; and

ii.        the remaining 75% of the securities will be released in 25% increments for each CDN $500,000 in revenue generated by Premium Products, up to a total of CDN $1,500,000, as reflected in the Company’s audited financial statements.

No finders’ fees payable were payable on this transaction, nor was there a change of control or any new control persons created. The acquisition did constitute a fundamental change, within the meaning of the policies of the CSE.

None of the securities issued in connection with the acquisition of Premium Products have been registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them will be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

On behalf of the Board of Directors of the Company,

TAAT® GLOBAL ALTERNATIVES INC.

 

“Joel Dumaresq”

 

Joel Dumaresq, CFO and Director

 

For further information, please contact:

 

TAAT® Investor Relations

1-604-687-2038

investor@taatglobal.com

 

THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.

About TAAT Global Alternatives, Inc.

TAAT is a consumer product company specializing in innovative alternatives to traditional CPG categories. With a commitment to quality and consumer satisfaction, TAAT operates from its Ohio distribution center, fulfilling orders and supporting a growing network of retail locations across the U.S.

For additional information, visit taatglobal.com 

Forward-Looking Statements

Certain information contained herein may constitute "forward-looking information" or "forward-looking statements" under Canadian securities legislation. Generally, forward-looking information can be identified by words such as "pro forma", "plans", "expects", "may", "should", "could", "will", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", or variations including negative variations thereof of such words and phrases that refer to certain actions, events or results that may, occur or be taken or achieved. Such forward-looking statements, including but not limited to statements relating to the expected development and operations of the Company, including market conditions, regulatory developments and the successful integration and performance of Premium Products LLC within TAAT’s broader operations which  involve risks, uncertainties and other factors which may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Corporation will not update any forward-looking statements or forward-looking information included herein, except as required by applicable securities laws.

 

The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.

 

This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.

 

Statement Regarding Third-Party Investor Relations Firms

 

Disclosures relating to investor relations firms retained by TAAT® Global Alternatives Inc. can be found under the Company's profile on www.sedarplus.ca.